Schuster SJ, et al. - The efficacy of CD19-directed chimeric antigen receptor (CTL019) therapy was determined in patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma. High rates of durable remission were shown, with recovery of B cells and immunoglobulins in some patients. The development of transient encephalopathy was noted in approximately one in three patients and severe cytokine-release syndrome developed in one in five patients.